Prothena Corporation PLC (NASDAQ:PRTA) insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $64.89, for a total value of $324,450.00. Following the completion of the transaction, the insider now directly owns 5,000 shares in the company, valued at $324,450. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Prothena Corporation PLC (PRTA) traded up 3.57% during mid-day trading on Wednesday, hitting $66.76. The stock had a trading volume of 431,379 shares. The firm’s market cap is $2.54 billion. The stock’s 50-day moving average price is $55.55 and its 200-day moving average price is $53.51. Prothena Corporation PLC has a 52-week low of $40.58 and a 52-week high of $68.18.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.33. The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.26 million. Prothena Corporation PLC had a negative net margin of 16,012.49% and a negative return on equity of 39.67%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.81) EPS. On average, analysts anticipate that Prothena Corporation PLC will post ($4.76) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Prothena Corporation PLC (NASDAQ:PRTA) Insider Sells 5,000 Shares of Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/19/insider-selling-prothena-corporation-plc-nasdaqprta-insider-sells-5000-shares-of-stock.html.

A number of hedge funds have recently made changes to their positions in PRTA. Victory Capital Management Inc. purchased a new stake in Prothena Corporation PLC during the first quarter worth $588,000. OMERS ADMINISTRATION Corp acquired a new position in Prothena Corporation PLC during the first quarter worth about $273,000. Russell Investments Group Ltd. acquired a new position in Prothena Corporation PLC during the fourth quarter worth about $528,000. American International Group Inc. increased its position in Prothena Corporation PLC by 5.3% in the first quarter. American International Group Inc. now owns 21,039 shares of the biotechnology company’s stock worth $1,174,000 after buying an additional 1,066 shares in the last quarter. Finally, Palo Alto Investors LLC increased its position in Prothena Corporation PLC by 6.2% in the first quarter. Palo Alto Investors LLC now owns 1,055,855 shares of the biotechnology company’s stock worth $58,906,000 after buying an additional 62,000 shares in the last quarter.

A number of research firms recently weighed in on PRTA. BidaskClub raised Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $70.00 price target on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. Jefferies Group LLC began coverage on Prothena Corporation PLC in a research note on Monday, July 10th. They set a “buy” rating and a $100.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $77.00 price target on shares of Prothena Corporation PLC in a research note on Monday, April 3rd. Finally, Zacks Investment Research downgraded Prothena Corporation PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, April 26th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Prothena Corporation PLC presently has an average rating of “Buy” and a consensus price target of $75.69.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.